INSMED Inc INSM
We are a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. 10-K, Item 1
- Employees
- 1,664
- Headquarters
- Bridgewater, NJ
- CEO
- William Lewis
- Next results
- around Feb 18, 2027
INSM among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
25 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 19, 2026 against Feb 20, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Receivables growing faster than revenueReceivables +170.8% ($52.0M to $140.9M) vs revenue +66.7% ($363.7M to $606.4M), +104.1 pts apart
-
Cash from operations −$935.0M vs net income −$1.3B (FY ending Dec 31, 2025)
9 more checks with nothing to note
-
Inventory +34.0% ($98.6M to $132.1M) vs revenue +66.7% ($363.7M to $606.4M), -32.8 pts apart
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Variable consideration in contracts with customers; Table of Contents
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
25 paragraphs in Risk Factors that were not in the 10-K filed Feb 20, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
In addition, advertising and promotion of any product candidate that obtains approval in the US is heavily scrutinized by the FDA, the Department of Justice, the Department of Health and Human Services’ Office of Inspector General, state attorneys general, members of Congress, other government agencies and the public. While physicians…
-
Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
In addition, the policies of the FDA, the EMA, the MHLW, and other comparable regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our products. Costs arising out of any regulatory developments could be time-consuming and expensive and could…
-
Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
Furthermore, professional societies, practice management groups, private health and science foundations and other organizations publish guidelines or recommendations to the healthcare and patient communities relating to such matters as usage, dosage, route of administration and use of concomitant therapies. Recommendations or guidelines…
-
Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
If we fail to obtain or maintain regulatory exclusivity for our product candidates, our business may be materially harmed. We may be unable to obtain, or may not be able to maintain, regulatory exclusivity for our products or product candidates, including exclusivity under the Hatch-Waxman Act, orphan drug exclusivity, Generating…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $245.4M | $305.2M | $363.7M | $606.4M |
| Net income | −$481.5M | −$749.6M | −$913.8M | −$1.3B |
| Operating cash flow | −$400.4M | −$536.2M | −$683.9M | −$935.0M |
| Free cash flow | −$410.3M | −$549.5M | −$705.8M | −$967.6M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$606.4M ▲ 66.7% in FY2025−$1.3B in FY2025−$967.6M in FY2025
Recent filings
7 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 3, 2026Sara Bonstein (Former Officer) gave notice of a planned sale of 10,261 shares worth about $1.1M Form 144, approximate sale date Nov 3, 2026
-
Planned saleOct 29, 2026Sara Bonstein (Chief Financial Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 328,363 shares, runs to Aug 9, 2027
-
Planned saleOct 29, 2026Michael A. Smith (Chief Legal Officer) ended a 10b5-1 trading plan reported in the 10-Q, up to 224,744 shares, runs to Jun 16, 2028
-
Planned saleOct 29, 2026William Lewis (Chief Executive Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 255,792 shares, runs to Jul 28, 2027
-
8-KOct 29, 2026Quarterly results 8-K item 2.02
About the company
INSMED Inc, Bridgewater, NJ · from the 10-K filed Feb 19, 2026
We are a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Our commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. To complement our internal research and development, we also actively evaluate in-licensing and acquisition opportunities for commercial products, product candidates and technologies.
- Headquarters
- Bridgewater, NJ
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Oct 29, 2026
- Incorporated in
- VA
Employees, at the top of the page: "As of December 31, 2025, we had a total of 1,664 full-time employees: 736 in research, clinical, regulatory, medical affairs and quality assurance; 107 in technical operations, manufacturing and quality control; 266 in general and administrative functions; and 555 in commercial activities" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 19, 2026 (open at SEC), compared with the 10-K filed Feb 20, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/INSM/export.csv") into a cell.